Fluence Announces Major Presence and Product Launch at GreenTech Amsterdam 2023
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today it will attend the 2023 GreenTech Amsterdam conference, which will include speaking sessions by Fluence industry experts Steve Graves, senior vice president of strategy and product, Timo Bongartz, general manager of EMEA, Theo Tekstra, technical director of EMEA, and Dr. David Hawley, principal scientist for Fluence. Fluence’s presence will also include an in-booth expert session with Dominique van Gruisen, managing director of Innexo BV.
The LED lighting leader also announced the launch of the newest generation of VYPR, a high-performance linear top light for greenhouse crops, which will be available for public viewing and demonstration at Fluence’s stand during GreenTech, the leading global meeting place for the horticulture industry. In addition to VYPR, attendees will also be able to interact with Fluence’s comprehensive product suite, including RAPTR, VYNE, SPYDR, RAZR and Wireless Flex Dimming fixtures.
“GreenTech Amsterdam provides the opportunity to meet with and speak alongside leaders advancing agriculture and technology from across the world,” said Timo Bongartz, general manager for EMEA at Fluence. “At Fluence, we are committed to helping the world grow smarter through innovative technology to drive better plant cultivation. It’s an honor to have Fluence prominently featured in speaking sessions at GreenTech, and we’re excited to introduce the newest VYPR LED technology to the Europe, Middle East and Africa region.”
Attendees can visit Fluence’s horticulture specialists from June 13 through June 15 at Stand 130 in Exhibit Hall 5 at the RAI Amsterdam Convention Center.
Fluence’s speaking sessions at GreenTech Amsterdam 2023 will include:
- Lights and Buds (June 13, 10:45 a.m. CET), featuring Dr. David Hawley, principal scientist for Fluence at the Plants Compounds Stage
- Complexity in Lighting (June 13, 12:15 p.m. CET), featuring Theo Tekstra, technical director of EMEA for Fluence at the Technology Stage
- Panel: Medicinal Cannabis (June 13, 1 p.m. CET), featuring Timo Bongartz, general manager of EMEA for Fluence at the Plant Compounds Stage
- Manipulating Medicinally Relevant Cannabis Chemistry with Light Environment (June 13, 3:20 p.m. CET), featuring Dr. David Hawley, principal scientist for Fluence at the Amtrium
- Experiences in Setting Up Complex Medical Cannabis Research Projects, to Innovate and Optimize Production (June 14, 11:00 a.m. CET), expert session at Fluence’s Stand 05.130, featuring Dominique van Gruisen, managing director of Innexo BV
- Public Health - Food Security, including a panel discussion on Endgame for Low Nutritional Food, Breaching Containment CEA and Pharmaceutical Solutions (June 14, 12:15 p.m. CET), featuring Steve Graves, senior vice president of strategy and product for Fluence at the Vertical Farming Stage
The latest extension of the VYPR series delivers a new level of flexibility and control to growers through dual-channel far-red capability. Adding an independent control channel for far-red light empowers growers with the ability to manipulate crop morphology and increase energy savings, opening new applications for growers of flowers, strawberries and cucumbers. The latest VYPR product is now available as an 800W platform, making it a one-to-one replacement for 1000W HPS fixtures while offering higher light intensity and lower energy consumption.
“The newest generation of Fluence’s VYPR product line is built to deliver growers exactly what they’ve been asking for: greater versatility, enhanced light distribution and higher output to increase crop yield, uniformity and quality,” said Graves. “Advancements in our understanding of light spectra have led to a more sophisticated product and a new tool to drive optimal crop performance and profitability.”
The latest VYPR product is designed to improve uniformity with wider light distribution, featuring a 150-degree optic across R8, R8F, R9 and R9F light spectra. It maintains a slim form factor and low-profile design but now offers more flexible installation options that make mounting faster and help reduce installation costs.
For more information on Fluence, visit www.fluence.science or stop by Exhibit Hall 5, Stand 130 at GreenTech Amsterdam 2023.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005062/en/
Contact information
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 160 93335045
For North America,
Callie Neatherlin
callie@redfancommunications.com
512-439-9720
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress29.9.2023 20:43:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community." Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Efficacy an
Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail29.9.2023 17:30:00 EEST | Press release
Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is pleased to announce their ranking on the 2023 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 earned its spot with three-year growth of 150%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the fourth consecutive year by The Globe and Mail,” remarked Darrell Heaps, Founder and CEO of Q4. “We are proud of the growth we have achieved as a company and this recognition is a true reflection of our dedication to helping our clients win in the capital markets through innovative technology on the Q4 Platform.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to bring the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application proc
GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine29.9.2023 16:15:00 EEST | Press release
GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in a combined company that will offer advanced early diagnosis and early identification of recurring cancer as well as potential therapies for several critical diseases such as pancreatic cancer and other solid tumors with poor life expectancy. The combined company will have a unique advantage: Renovaro Biosciences’ pre-clinical and clinical trial data could be utilized to accelerate GEDi Cube’s AI capabilities that, in turn, could potentially help to accelerate Renovaro’s development of potential new therapies. AI will be used to advance the fields of diagnosis and treatment with
Offshore Windfarm Hollandse Kust Zuid Inaugurated29.9.2023 14:53:00 EEST | Press release
Today, Dutch King Willem-Alexander jointly with the board members of Vattenfall, BASF, and Allianz officially inaugurated the offshore wind farm Hollandse Kust Zuid 1-4. The wind farm is in the North Sea, 18-36 kilometers off the Dutch coast between the towns of Scheveningen and Zandvoort. The 139 turbines have a total capacity of 1.5 GW, making it one of the largest offshore wind farms in the world. The annual electricity production is expected to equal the consumption of 1.5 million households. Hollandse Kust Zuid is owned by Vattenfall, BASF, and Allianz. The wind farm is expected to be fully operational in 2024 and will be serviced out of the port of IJmuiden. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230929518869/en/ Inauguration Hollandse Kust Zuid wind farm. From left to right: Helene Biström (Senior Vice President, Head of Business Area Wind Vattenfall), Martijn Hagens (CEO Vattenfall Netherlands), His Majesty K
The Estée Lauder Companies Launches 2023 Breast Cancer Campaign: Beautifully United to Help End Breast Cancer29.9.2023 14:00:00 EEST | Press release
For more than 30 years, The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) has been dedicated to advancing the possibility of a breast cancer-free world for all. This October, The Estée Lauder Companies (ELC) honors Breast Cancer Awareness Month by launching The Campaign in support of the global breast cancer community. As ELC’s largest corporate social impact program, The Campaign continues to inspire purpose-driven action and is a cornerstone of the company’s social investments in women’s advancement, health and education. Through The Campaign, ELC has also been a longstanding supporter of women in science, research and medicine – funding numerous grants and programs around the world and accelerating opportunities for women in STEM. The Campaign was founded by Evelyn H. Lauder in 1992 with the launch of the iconic Pink Ribbon. At a time when breast cancer wasn’t spoken about openly, Evelyn and ELC saw an opportunity to bring awareness to the disease and address stigmas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom